First participants recruited across PROTID sites

22-08-2022

In June 2022 the first participants were enrolled in the PROTID study. After succesful Site Initiation Visits performed by the study Sponsor (NIMR-MMRC, Mbeya, TZA), all sites were able to start enrolment by June. See for a full description of the study protocol: Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial | Trials | Full Text (biomedcentral.com)

Trial activities in Kampala (Uganda):